287. Comparison of Turnaround Time (TAT) and Time to Oseltamivir Discontinuation between Two Respiratory Viral Panel Testing (RVP) Methodologies
Session: Poster Abstract Session: Diagnostic Microbiology; Novel Molecular Methods
Thursday, October 3, 2013
Room: The Moscone Center: Poster Hall C
Background: Multiplex PCR has been shown to be more sensitive with more rapid TAT compared to other methodologies for respiratory viral testing.  Our microbiology laboratory switched from Luminex xTAG® RVP which detects 12 respiratory viruses and has an assay time of 8.5 hours to Biofire Diagnostics, Inc. FilmArray® RVP testing, which detects 17 respiratory viral and 3 bacterial targets and has an assay time of 1.2 hours.  We sought to compare the actual TAT between the two testing methods and determine time to discontinuation of empiric oseltamivir.

Methods: All adult inpatients with an RVP test result reported between 12/1/2011-2/28/2012 performed on Luminex xTAG® and 12/1/2012-2/28/2013 performed on FilmArray® were evaluated for average TAT (defined as the time period between when the specimen was received to the time when the result was reported).  Among patients with influenza negative RVP results, the time to discontinuation of empiric oseltamivir was also determined.

Results: The average TAT for the Luminex xTAG® RVP performed 2-3x/week between 12/1/2011-2/28/2012 (N=230 assays) was 46.4 hours compared to an average TAT of 3.1 hours (p<0.001) for FilmArray® performed 24 hours a day/7days per week from 12/1/2012-2/28/13 (N=872 assays).  The average time to discontinuation of empiric oseltamivir among patients with an RVP negative for influenza was 4 and 2 days for the Luminex® xTAG (N=42) and FilmArray®(N=75) groups, respectively (p<0.001). 

Conclusion: Use of FilmArray® RVP testing has important clinical advantages compared to Luminex xTAG®.  Consistent with previous literature showing that the TAT for FilmArray® is significantly shorter than for Luminex xTAG® RVP testing, we observed an average TAT 43.3 hours shorter.  We also found that the average duration of empiric oseltamivir was reduced by 50% when the RVP was performed with FilmArray®.

Natasha Pettit, PharmD1, Scott Matushek, MS2, Angella Charnot-Katsikas, MD2, Vera Tesic, MD, MS2, Sue Boonlayangoor, MS2, Benjamin Brielmaier, PharmD3 and Jennifer Pisano, MD4, (1)Pharmacy Services, The University of Chicago Medicine, Chicago, IL, (2)Pathology, The University of Chicago Medicine, Chicago, IL, (3)The University of Chicago Medicine, Chicago, IL, (4)Infectious Diseases and Global Health, The University of Chicago Medicine, Chicago, IL


N. Pettit, None

S. Matushek, None

A. Charnot-Katsikas, None

V. Tesic, None

S. Boonlayangoor, None

B. Brielmaier, None

J. Pisano, None

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.